Isotretinoin

Acne Vulgaris

Volumn , Issue , 2011, Pages 134-145

  Osofsky, Michael G ^a   Strauss, John S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897482354     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (67)

1. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble a vitamin. J Exp Med 1925; 42:753-777.
2. Bollag W. The development of retinoids in experimental and clinical oncology and dermatology. J Am Acad Dermatol 1983; 9:797-805.
3. Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300:329-333.
4. Peck GL, Olsen TG, Butkus D, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6:735-745.
5. Khoo KC, Reik D, Colburn WA. Pharmacokinetics of isotretinoin following a single oral dose. J Clin Pharmacol 1982; 22:395-402.
6. Brazzell RK, Vane FM, Ehmann CW, et al. Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 1983; 24:695-702.
7. Colburn WA, Gibson DM, Wiens RE, et al. Food increases the bioavailability of isotretinoin. J Clin Pharmacol 1983; 23:534-539.
8. Strauss JS, Stewart ME, Downing DT. The effect of 13-cis-retinoic acid on sebaceous glands. Arch Dermatol 1987; 123:1538a-1541a.
9. Strauss JS, Stranieri AM. Changes in long-term sebum production from isotretinoin therapy. J Am Acad Dermatol 1982; 6:751-756.
10. Strauss JS, Stranieri AM, Farrell LN, et al. The effect of marked inhibition of sebum production with 13cis-retinoic acid on skin surface lipid composition. J Invest Dermatol 1980; 74:66-67.
11. Nelson AM, Gilliland KL, Cong Z, et al. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006; 126:2178-2189.
12. Nelson AM, Zhao W, Gilliland KL, et al. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol 2009; 1:177-187.
13. Nelson AM, Zhao W, Gilliland KL, et al. Early gene changes induced by isotretinoin in the skin provide clues to its mechanism of action. Dermatoendocrinol 2009; 1:100-101.
14. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10:490-496.
15. Al-Mutairi N, Manchanda Y, Nour-Eldin O, et al. Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait. J Drugs Dermatol 2005; 4:369-373.
16. Chivot M, Midoun H. Isotretinoin and acne-a study of relapses. Dermatologica 1990; 180:240-243.
17. Harms M, Masouye I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 1986; 172:148-153.
18. Haryati I, Jacinto SS. Profile of acne patients in the Philippines requiring a second course of oral isotretinoin. Int J Dermatol 2005; 44:999-1001.
19. Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2007; 157(6):1240-1248.
20. Lehucher-Ceyrac D, de La Salmoniere P, Chastang C, et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198:278-283.
21. Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186:123-128.
22. Ng PP, Goh CL. Treatment outcome of acne vulgaris with oral isotretinoin in 89 patients. Int J Dermatol 1999; 38:213-216.
23. Quereux G, Volteau C, N'Guyen JM, et al. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 2006; 212:168-176.
24. Shahidullah M, Tham SN, Goh CL. Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol 1994; 33:60-63.
25. Stainforth JM, Layton AM, Taylor JP, et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129:297-301.
26. White GM, Chen W, Yao J, et al. Recurrence rates after the first course of isotretinoin. Arch Dermatol 1998; 134:376-378.
27. Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985; 313:981-985.
28. McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992; 87:1855-1858.
29. Zech LA, Gross EG, Peck GL, et al. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. Arch Dermatol 1983; 119:987-993.
30. Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134-2139.
31. Rodondi N, Darioli R, Ramelet A, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Int Med 2002; 136:582-589.
32. Zane LT, Leyden WA, Marqueling AL, et al. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142:1016-1022.
33. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114(pt 1A):155-180.
34. DiGiovanna JJ, Langman CB, Tschen EH, et al. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol 2004; 51:709-717.
35. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313:837-841.
36. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26:599-606.
37. Lynberg MC, Khoury MJ, Lammer EJ, et al. Sensitivity, specificity, and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance. Teratology 1990; 42:513-519.
38. Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol 1993; 7:175-177.
39. Pennes DR, Ellis CN, Madison KC, et al. Early skeletal hyperostoses secondary to 13-cis-retinoic acid. AJR Am J Roentgenol 1984; 142:979-983.
40. Ellis CN, Pennes DR, Martel W, et al. Radiographic bone surveys after isotretinoin therapy for cystic acne. Acta Derm Venereol 1985; 65:83-85.
41. Ellis CN, Madison KC, Pennes DR, et al. Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol 1984; 10:1024-1029.
42. Kocijancic M. 13-Cis-Retinoic acid and bone density. Int J Dermatol 1995; 34:733-734.
43. Leachman SA, Insogna KL, Katz L, et al. Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol 1999; 135:961-965.
44. Margolis DJ, Attie M, Leyden JJ. Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 1996; 132:769-774.
45. Lenchik L, Leib ES, Hamdy RC, et al. Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001. J Clin Densitom 2002; 5(suppl):S1-S3.
46. Hamdy RC, Petak SM, Lenchik L, International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. Which central dual X-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom 2002; 5(suppl):S11-S18.
47. Hazen PG, Carney JF, Walker AE, et al. Depression-a side effect of 13-cis-retinoic acid therapy. J Am Acad Dermatol 1983; 9:278-279.
48. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136:1231-1236.
49. Hersom K, Neary MP, Levaux HP, et al. Isotretinoin and antidepressant pharmacotherapy:a prescription sequence symmetry analysis. J Am Acad Dermatol 2003; 49:424-432.
50. Chia CY, Lane W, Chibnall J, et al. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol 2005; 141:557-560.
51. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2007; 26:210-220.
52. Rubinow DR, Peck GL, Squillace KM, et al. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987; 17:25-32.
53. Hahm BJ, Min SU, Yoon MY, et al. Changes of psychiatric parameters and their relationships by oral isotretinoin in acne patients. J Dermatol 2009; 36:255-261.
54. Kaymak Y, Kalay M, Ilter N, et al. Incidence of depression related to isotretinoin treatment in 100 acne vulgaris patients. Psychol Rep 2006; 99:897-906.
55. Kellett SC, Gawkrodger DJ. A prospective study of the responsiveness of depression and suicidal ideation in acne patients to different phases of isotretinoin therapy. Eur J Dermatol 2005; 15:484-488.
56. Kaymak Y, Taner E, Taner Y. Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents. Int J Dermatol 2009; 48:41-46.
57. Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry 2008; 69:526-532.
58. Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol 2008; 144:1197-1199; discussion 1234-1235.
59. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998; 134:454-458.
60. Newton JN, Mallon E, Klassen A, et al. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137:563-567.
61. Reniers DE, Howard JM. Isotretinoin-induced inflammatory bowel disease in an adolescent. Ann Pharmacother 2001; 35:1214-1216.
62. Passier JL, Srivastava N, van Puijenbroek EP. Isotretinoin-induced inflammatory bowel disease. Neth J Med 2006; 64:52-54.
63. Reddy D, Siegel CA, Sands BE, et al. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol 2006; 101:1569-1573.
64. Crockett SD, Gulati A, Sandler RS, et al. A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol 2009; 104:2387-2393.
65. Bernstein CN, Nugent Z, Longobardi T, et al. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol 2009; 104:2774-2778.
66. Godfrey KM, James MP. Treatment of severe acne with isotretinoin in patients with inflammatory bowel disease. Br J Dermatol 1990; 123:653-655.
67. Loftus CG, Loftus EV Jr., Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13:254-261.